tiprankstipranks
Trending News
More News >

ImmuPharma Shows Strong Progress and Reduced Losses

ImmuPharma Shows Strong Progress and Reduced Losses

ImmuPharma (GB:IMM) has released an update.

Confident Investing Starts Here:

ImmuPharma PLC reported a reduction in its operating loss to £0.4 million for the first half of 2024, down from £0.8 million in the previous year, alongside advancements in their P140 autoimmune technology platform, including a new Phase 3 study for SLE and preparations for a Phase 2/3 study for CIDP. The company has also divested its shares in Incanthera, realizing £1.5 million and retaining significant warrants, all contributing to a strengthened financial position and continued focus on strategic partnerships and clinical progress.

For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App